Sweden
· Delayed Price · Currency is SEK AstraZeneca Statistics
Total Valuation
AstraZeneca has a market cap or net worth of SEK 2.77 trillion. The enterprise value is 3.06 trillion.
| Market Cap | 2.77T |
| Enterprise Value | 3.06T |
Important Dates
The next estimated earnings date is Tuesday, November 12, 2024.
| Earnings Date | Nov 12, 2024 |
| Ex-Dividend Date | Aug 8, 2024 |
Share Statistics
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.16% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 1.54B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.31 |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 16.65, with an EV/FCF ratio of 30.63.
| EV / Earnings | 44.82 |
| EV / Sales | 5.84 |
| EV / EBITDA | 16.65 |
| EV / EBIT | 23.28 |
| EV / FCF | 30.63 |
Financial Position
The company has a current ratio of 0.89, with a Debt / Equity ratio of 84.97.
| Current Ratio | 0.89 |
| Quick Ratio | 0.69 |
| Debt / Equity | 84.97 |
| Debt / EBITDA | 1.95 |
| Debt / FCF | 3.57 |
| Interest Coverage | 9.65 |
Financial Efficiency
Return on equity (ROE) is 16.74% and return on invested capital (ROIC) is 10.91%.
| Return on Equity (ROE) | 16.74% |
| Return on Assets (ROA) | 7.68% |
| Return on Capital (ROIC) | 10.91% |
| Revenue Per Employee | 5.79M |
| Profits Per Employee | 759,256 |
| Employee Count | 89,900 |
| Asset Turnover | 0.49 |
| Inventory Turnover | 1.59 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +19.81% in the last 52 weeks. The beta is 0.15, so AstraZeneca's price volatility has been lower than the market average.
| Beta (5Y) | 0.15 |
| 52-Week Price Change | +19.81% |
| 50-Day Moving Average | 1,695.89 |
| 200-Day Moving Average | 1,512.84 |
| Relative Strength Index (RSI) | 64.03 |
| Average Volume (20 Days) | 197,013 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, AstraZeneca had revenue of SEK 520.76 billion and earned 68.26 billion in profits. Earnings per share was 43.66.
| Revenue | 520.76B |
| Gross Profit | 430.24B |
| Operating Income | 130.86B |
| Pretax Income | 82.10B |
| Net Income | 68.26B |
| EBITDA | 179.90B |
| EBIT | 130.86B |
| Earnings Per Share (EPS) | 43.66 |
Balance Sheet
The company has 75.00 billion in cash and 356.60 billion in debt, giving a net cash position of -281.60 billion.
| Cash & Cash Equivalents | 75.00B |
| Total Debt | 356.60B |
| Net Cash | -281.60B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 419.70B |
| Book Value Per Share | 270.18 |
| Working Capital | -33.63B |
Cash Flow
In the last 12 months, operating cash flow was 117.28 billion and capital expenditures -17.41 billion, giving a free cash flow of 99.86 billion.
| Operating Cash Flow | 117.28B |
| Capital Expenditures | -17.41B |
| Free Cash Flow | 99.86B |
| FCF Per Share | n/a |
Margins
Gross margin is 82.62%, with operating and profit margins of 25.13% and 13.11%.
| Gross Margin | 82.62% |
| Operating Margin | 25.13% |
| Pretax Margin | 15.77% |
| Profit Margin | 13.11% |
| EBITDA Margin | 34.55% |
| EBIT Margin | 25.13% |
| FCF Margin | 19.18% |
Dividends & Yields
AstraZeneca does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | 3.66% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 69.29% |
| Buyback Yield | -0.16% |
| Shareholder Yield | -0.16% |
| Earnings Yield | 2.45% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |